初诊18F-FDG PET/CT中SUVmax高于20与未知原发灶癌症患者较好生存相关
在West German Cancer Center Essen治疗的154例未知原发灶癌症(CUP)患者中,76例在初诊时接受了18F-FDG PET/CT。PET/CT亚组内SUVmax高于20与总生存显著更优相关(中位OS未达到 vs 32.0个月;HR 0.261;95%CI 0.095-0.713;P=0.009)。作者认为该回顾性结果提示SUVmax高于20是CUP的有利预后因素,值得进一步前瞻性研究验证。
要点
- 154例CUP患者中76例初诊时行18F-FDG PET/CT,全分析集中位OS为20.0个月。
- PET/CT亚组内SUVmax高于20者OS显著更优(中位OS未达到 vs 32.0个月)。
- HR 0.261(95%CI 0.095-0.713;P=0.009),作者认为需进一步前瞻性研究验证。
核心结论
- 作者认为初诊18F-FDG PET/CT上SUVmax高于20是CUP患者的有利预后因素,该发现值得进一步前瞻性研究验证。
研究设计与样本
- 回顾性研究,在West German Cancer Center Essen治疗的154例CUP患者中比较初诊时接受与未接受18F-FDG PET/CT者的总生存,其中76例接受了18F-FDG PET/CT。
主要发现
- 全分析集中位总生存为20.0个月。
- PET/CT亚组内SUVmax高于20与总生存显著更优相关(中位OS未达到 vs 32.0个月;HR 0.261;95%CI 0.095-0.713;P=0.009)。
关键数值与推荐
- PET/CT亚组内SUVmax高于20者的中位OS未达到,SUVmax不高于20者为32.0个月。
- SUVmax高于20与总生存的HR为0.261(95%CI 0.095-0.713;P=0.009)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文称本研究为回顾性工作。
- 原文结论指出该发现值得进一步前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer of unknown primary (CUP) is a heterogeneous entity with a limited prognosis. Novel prognostic markers are needed for patient stratification in prospective clinical trials exploring innovative therapies. Methods: In CUP patients treated at the West German Cancer Center Essen, the prognostic value of 18F-FDG PET/CT at the initial diagnostic workup was analyzed by comparing overall survival (OS) in patients who underwent 18F-FDG PET/CT with those who did not. Results: Of 154 patients with a CUP diagnosis, 76 underwent 18F-FDG PET/CT at the initial diagnostic workup. The median overall survival (OS) of the full analysis set was 20.0 mo. Within the PET/CT subgroup, an SUVmax above 20 was associated with significantly superior OS (median OS, not reached vs. 32.0 mo; hazard ratio, 0.261; 95% CI, 0.095-0.713; P = 0.009). Conclusion: Our retrospective work shows that an SUVmax above 20 on 18F-FDG PET/CT at the initial diagnostic workup is a favorable prognostic factor in patients with CUP. This finding deserves further prospective studies for validation.
引用
- Zaun G, Weber M, Metzenmacher M, et al. SUVmax Above 20 in 18F-FDG PET/CT at Initial Diagnostic Workup Associates with Favorable Survival in Patients with Cancer of Unknown Primary. J Nucl Med. 2023. PMID: 37321823. doi:10.2967/jnumed.122.265161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。